Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 649

1.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.

J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219. [Epub ahead of print]

2.

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.

Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G.

Cancer Immunol Res. 2018 Dec;6(12):1453-1458. doi: 10.1158/2326-6066.CIR-17-0659. Epub 2018 Oct 1.

PMID:
30275274
3.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.

Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M.

Br J Cancer. 2018 Sep;119(6):670-674. doi: 10.1038/s41416-018-0207-6. Epub 2018 Sep 11.

PMID:
30202085
4.

Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.

Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V, Meir A, Kubi A, Levy M, Zikich D, Zeltzer LA, Brezinger K, Schachter J, Nagler A, Besser MJ, Toren A.

Am J Hematol. 2018 Dec;93(12):1485-1492. doi: 10.1002/ajh.25274. Epub 2018 Sep 26.

PMID:
30187944
5.

FibroSURE and elastography poorly predict the severity of liver fibrosis in Fontan-associated liver disease.

Schachter JL, Patel M, Horton SR, Mike Devane A, Ewing A, Abrams GA.

Congenit Heart Dis. 2018 Sep;13(5):764-770. doi: 10.1111/chd.12650. Epub 2018 Aug 12.

PMID:
30101472
6.

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.

Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.

Eur J Cancer. 2018 Sep;101:229-235. doi: 10.1016/j.ejca.2018.06.030. Epub 2018 Aug 7.

PMID:
30096703
7.

Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.

Schultz MK Jr, Gentzel R, Usenovic M, Gretzula C, Ware C, Parmentier-Batteur S, Schachter JB, Zariwala HA.

Neurobiol Dis. 2018 Oct;118:161-176. doi: 10.1016/j.nbd.2018.07.003. Epub 2018 Jul 7.

PMID:
30049665
8.

ADAR1-mediated regulation of melanoma invasion.

Nemlich Y, Baruch EN, Besser MJ, Shoshan E, Bar-Eli M, Anafi L, Barshack I, Schachter J, Ortenberg R, Markel G.

Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.

9.

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.

Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ.

Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230. doi: 10.1007/s00262-018-2174-4. Epub 2018 May 29.

PMID:
29845338
10.

Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.

Wang X, Smith K, Pearson M, Hughes A, Cosden ML, Marcus J, Hess JF, Savage MJ, Rosahl T, Smith SM, Schachter JB, Uslaner JM.

PLoS One. 2018 Apr 6;13(4):e0195486. doi: 10.1371/journal.pone.0195486. eCollection 2018.

11.

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G.

Neoplasia. 2018 Apr;20(4):401-409. doi: 10.1016/j.neo.2018.01.012. Epub 2018 Mar 17.

12.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.

PMID:
29528792
13.

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.

Autoimmun Rev. 2018 Mar;17(3):284-289. doi: 10.1016/j.autrev.2018.01.003. Epub 2018 Jan 16.

PMID:
29341936
14.

Plasmodium falciparum invasion and intraerythrocytic development are impaired by 2', 3'-dialdehyde adenosine.

Silva LS, Prado GC, Quintana PG, Heise N, Miranda KR, Torres EJL, Persechini PM, de Sá Pinheiro AA, Schachter J.

Microbes Infect. 2018 Mar;20(3):205-211. doi: 10.1016/j.micinf.2017.11.015. Epub 2017 Dec 15.

PMID:
29253662
15.

Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma.

Galore-Haskel G, Baruch EN, Berg AL, Barshack I, Zilinsky I, Avivi C, Besser MJ, Schachter J, Markel G.

Oncotarget. 2017 Sep 14;8(59):99580-99586. doi: 10.18632/oncotarget.20884. eCollection 2017 Nov 21.

16.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
17.

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.

Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, Yunger S, Markel G, Schachter J, Besser MJ.

Front Immunol. 2017 Oct 10;8:1211. doi: 10.3389/fimmu.2017.01211. eCollection 2017.

18.

POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages.

Pimenta-Dos-Reis G, Torres EJL, Quintana PG, Vidal LO, Dos Santos BAF, Lin CS, Heise N, Persechini PM, Schachter J.

Purinergic Signal. 2017 Dec;13(4):611-627. doi: 10.1007/s11302-017-9588-x. Epub 2017 Oct 11.

19.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.

PMID:
28961465
20.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.

J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.

PMID:
28915085
21.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM.

N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.

22.

Effects of obesity on depression: A role for inflammation and the gut microbiota.

Schachter J, Martel J, Lin CS, Chang CJ, Wu TR, Lu CC, Ko YF, Lai HC, Ojcius DM, Young JD.

Brain Behav Immun. 2018 Mar;69:1-8. doi: 10.1016/j.bbi.2017.08.026. Epub 2017 Sep 6. Review.

PMID:
28888668
23.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
24.

Perioperative BRAF inhibitors in locally advanced stage III melanoma.

Zippel D, Markel G, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S.

J Surg Oncol. 2017 Dec;116(7):856-861. doi: 10.1002/jso.24744. Epub 2017 Jun 26.

PMID:
28650570
25.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698
26.

Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion.

Hadfield J, Harris SR, Seth-Smith HMB, Parmar S, Andersson P, Giffard PM, Schachter J, Moncada J, Ellison L, Vaulet MLG, Fermepin MR, Radebe F, Mendoza S, Ouburg S, Morré SA, Sachse K, Puolakkainen M, Korhonen SJ, Sonnex C, Wiggins R, Jalal H, Brunelli T, Casprini P, Pitt R, Ison C, Savicheva A, Shipitsyna E, Hadad R, Kari L, Burton MJ, Mabey D, Solomon AW, Lewis D, Marsh P, Unemo M, Clarke IN, Parkhill J, Thomson NR.

Genome Res. 2017 Jul;27(7):1220-1229. doi: 10.1101/gr.212647.116. Epub 2017 Jun 6.

27.

Adoptive T cell therapy: An overview of obstacles and opportunities.

Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G.

Cancer. 2017 Jun 1;123(S11):2154-2162. doi: 10.1002/cncr.30491. Review.

28.

The Art of Feedback in Medical Practice.

Schachter J.

J Obstet Gynaecol Can. 2017 Aug;39(8):682-683. doi: 10.1016/j.jogc.2017.03.088. Epub 2017 May 11. No abstract available.

PMID:
28506587
29.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
30.

Adoptive Cell Therapy for Metastatic Melanoma.

Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ.

Cancer J. 2017 Jan/Feb;23(1):48-53. doi: 10.1097/PPO.0000000000000240. Review.

PMID:
28114254
31.

Stability Studies on Dry Swabs and Wet Mailed Swabs for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Aptima Assays.

Moncada J, Clark CB, Holden J, Hook EW 3rd, Gaydos CA, Schachter J.

J Clin Microbiol. 2017 Mar;55(3):971-977. doi: 10.1128/JCM.02235-16. Epub 2017 Jan 11.

32.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K.

Ann Oncol. 2017 Mar 1;28(3):634-641. doi: 10.1093/annonc/mdw641.

PMID:
27993793
33.

Letter to the Editor.

Schachter J.

Psychodyn Psychiatry. 2016 fall;44(3):495. doi: 10.1521/pdps.2016.44.3.495. No abstract available.

PMID:
27603808
34.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A.

Eur J Cancer. 2016 Nov;67:46-54. doi: 10.1016/j.ejca.2016.07.018. Epub 2016 Sep 2.

35.

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.

Liang SH, Chen JM, Normandin MD, Chang JS, Chang GC, Taylor CK, Trapa P, Plummer MS, Para KS, Conn EL, Lopresti-Morrow L, Lanyon LF, Cook JM, Richter KE, Nolan CE, Schachter JB, Janat F, Che Y, Shanmugasundaram V, Lefker BA, Enerson BE, Livni E, Wang L, Guehl NJ, Patnaik D, Wagner FF, Perlis R, Holson EB, Haggarty SJ, El Fakhri G, Kurumbail RG, Vasdev N.

Angew Chem Int Ed Engl. 2016 Aug 8;55(33):9601-5. doi: 10.1002/anie.201603797. Epub 2016 Jun 29.

36.

How can we improve outcomes of chlamydia control programmes?

Schachter J, Chow JM.

Lancet Infect Dis. 2016 Sep;16(9):989-990. doi: 10.1016/S1473-3099(16)30131-1. Epub 2016 Jun 8. No abstract available.

37.

Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy.

Ben-Ami E, Schachter J.

Melanoma Manag. 2016 Jun;3(2):137-147. doi: 10.2217/mmt-2016-0002. Epub 2016 May 25. Review.

38.

Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.

Ben-Avi R, Itzhaki O, Simansky D, Zippel D, Markel G, Ben Nun A, Schachter J, Besser MJ.

J Immunother. 2016 Jun;39(5):218-22. doi: 10.1097/CJI.0000000000000124.

PMID:
27163742
39.

Azithromycin versus Doxycycline for Chlamydia.

Schachter J.

N Engl J Med. 2016 May 5;374(18):1786. doi: 10.1056/NEJMc1600830. No abstract available.

PMID:
27144857
40.

Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Holahan M, O'Malley S, Purcell M, Riffel K, Li J, Balsells J, OBrien JA, Melquist S, Soriano A, Zhang X, Ogawa A, Xu S, Joshi E, Della Rocca J, Hess FJ, Schachter J, Hesk D, Schenk D, Struyk A, Babaoglu K, Lohith TG, Wang Y, Yang K, Fu J, Evelhoch JL, Coleman PJ.

J Med Chem. 2016 May 26;59(10):4778-89. doi: 10.1021/acs.jmedchem.6b00166. Epub 2016 May 5.

PMID:
27088900
41.

CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis.

Markel G, Imazio M, Koren-Morag N, Galore-Haskel G, Schachter J, Besser M, Cumetti D, Maestroni S, Altman A, Shoenfeld Y, Brucato A, Adler Y.

Oncotarget. 2016 Apr 5;7(14):17885-95. doi: 10.18632/oncotarget.7530.

42.

Point-of-care tests using enzyme detection to diagnose Chlamydia trachomatis infection do not work. But when they fail in clinical trials, they reappear under different names.

Schachter J.

Sex Transm Infect. 2016 Sep;92(6):406-7. doi: 10.1136/sextrans-2015-052508. Epub 2016 Feb 19. No abstract available.

PMID:
26895879
43.

SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.

Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G.

Oncotarget. 2016 May 24;7(21):30166-77. doi: 10.18632/oncotarget.7379.

44.

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.

Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y.

Oncotarget. 2016 Feb 2;7(5):5110-7. doi: 10.18632/oncotarget.6960.

45.

Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burns.

Haik J, Nardini G, Goldman N, Galore-Haskel G, Harats M, Zilinsky I, Weissman O, Schachter J, Winkler E, Markel G.

Oncotarget. 2016 Jan 19;7(3):2220-8. doi: 10.18632/oncotarget.6789.

46.

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.

Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, Zikich D, Besser MJ, Schachter J, Markel G.

J Immunol Res. 2015;2015:902137. doi: 10.1155/2015/902137. Epub 2015 Nov 25.

47.

Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.

Zikich D, Schachter J, Besser MJ.

Immunotherapy. 2016;8(1):35-43. doi: 10.2217/imt.15.99. Epub 2015 Dec 10. Review.

PMID:
26653685
48.

Tumor-Infiltrating Lymphocytes: Clinical Experience.

Besser MJ, Shapira-Frommer R, Schachter J.

Cancer J. 2015 Nov-Dec;21(6):465-9. doi: 10.1097/PPO.0000000000000154. Review.

PMID:
26588677
49.

What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion.

Dukers-Muijrers NH, Schachter J, van Liere GA, Wolffs PF, Hoebe CJ.

BMC Infect Dis. 2015 Nov 17;15:533. doi: 10.1186/s12879-015-1280-6.

50.

Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.

d'Abramo C, Acker CM, Schachter JB, Terracina G, Wang X, Forest SK, Davies P.

Neurobiol Aging. 2016 Jan;37:58-65. doi: 10.1016/j.neurobiolaging.2015.09.017. Epub 2015 Oct 21.

Supplemental Content

Loading ...
Support Center